Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Multiple Myeloma 2Breast Neoplasms 2Uterine Cervical Dysplasia 1Sarcoma 1Polycystic Ovary Syndrome 1Peripheral Nervous System Diseases 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Leukemia 1Insulin Resistance 1Diabetes Mellitus 1Central Nervous System Neoplasms 1Cardiovascular Diseases 1Cardiotoxicity 1Burns 1

Interventions

Echocardiography 14Doxorubicin 10Exercise 8Electrocardiography 7Trastuzumab 6Cyclophosphamide 5Carvedilol 5Docetaxel 3Atorvastatin 3salicylhydroxamic acid 2sacubitril and valsartan sodium hydrate drug combination 2empagliflozin 2dapagliflozin 2Tablets 2Social Determinants of Health 2Silymarin 2Magnetic Resonance Spectroscopy 2Ivabradine 2High-Intensity Interval Training 2Exercise Test 2Chemoradiotherapy 2Blood Specimen Collection 2Bisoprolol 2Antineoplastic Agents 2Anthracyclines 2sulforaphane 1schizandrin 1pegfilgrastim 1nicotinamide-beta-riboside 1mitoquinone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Cardiotoxicity × Fenofibrate × Clear all
NCT06155331 2025-08-19

Evaluation of Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients

Tanta University

Phase 2 Completed
44 enrolled
Breast

Breast Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡